Interview with John Montgomery , CEO, Alphapharm
Alphapharm recently celebrated its 25th anniversary. In light of this significant milestone, would you give us a brief introduction to the company? Alphapharm started in 1982 in Brisbane with a…
Address: Level 1, 30 The Bond, 30-34 Hickson Road, Millers Point NSW 2000
Tel: (602) 9298 3999
Web: http://www.alphapharm.com.au/
Alphapharm has been researching, developing and making generic medicines in Australia for more than 25 years. Millions of Australians take an Alphapharm generic medicine every day. Alphapharm has become the largest supplier of medicines to the subsidised PBS and Australia’s leader in generic medicines.
Alphapharm medicines are available Australia-wide. Alphapharm medicines are made to the highest global quality standards and exported to more than 50 countries, including those in Europe and the US.
Globally, Alphapharm is part of Mylan whose broad offering includes the world’s second largest portfolio of active pharmaceutical ingredients (APIs) and a powerful pipeline with more than 200 applications or dossiers pending regulatory approval. The structure of Alphapharm enables the company to leverage Mylan’s global platform while maintaining a very strong emphasis on meeting local market needs and expectations.
Cardiology, Pain Management, Osteoporosis, Smoking Cessation, Weight Management
Alphapharm recently celebrated its 25th anniversary. In light of this significant milestone, would you give us a brief introduction to the company? Alphapharm started in 1982 in Brisbane with a…
How have PBS reforms impacted Allergan in Australia? The PBS is a very good system that provides Australians with equity of access and has worked well in the country for…
Alphapharm recently celebrated its 25th anniversary. In light of this significant milestone, would you give us a brief introduction to the company? Alphapharm started in 1982 in Brisbane with a…
What impact have the PBS reforms had on sanofi-aventis in Australia? Sanofi-aventis has one of the largest portfolios of medicines in Australia, with over 240 products in the key areas…
Would you please introduce Pretium’s specific service offerings, and the focus within these? Pretium offers a comprehensive range of integrated services across our 4 lines of business – Market Intelligence,…
What are some of the challenges facing pharmaceutical companies in Australia today? There are four major challenges within the Australian pharmaceutical industry at the moment. The increasing complexity of getting…
As ASMI President and Managing Director of Galderma, would you please give us a brief overview of the Australian OTC market and Galderma’s role therein? Galderma is a leading player…
What impact have the PBS reforms had on Amgen in Australia? From a company perspective, biotechnology companies exist in a competitive space. They have predominantly niche medicines with significant competitive…
2006 marked a major milestone, with the Pharmaceutical Industry Action Agenda transformed from a Government-industry initiative into an industry-driven agenda, and the resulting creation of the Pharmaceutical Industry Council (PIC).…
One of the hot topics in the industry is the impact of PBS reforms. Can you speak to recent influence of PBS reforms affecting Novotech’s services in Australia? In our…
What impact have the PBS reforms had on Nycomed? As most mid size Pharma companies that operate in a setting of mass market prescription medicines, Nycomed is also experiencing the…
New Government health priorities and policies, highlighting those concerning preventive health. The Rudd Labor Government’s goal in health is to create a modern health system designed for the health needs…
How have your experiences at Quintiles, Astra, Baxter, and Innovex – covering the spectrum from small to large pharma in addition to the service side – helped in managing IMS…
See our Cookie Privacy Policy Here
